NCT03668548

Brief Summary

The purpose of this study is to assess the effects of 10-weeks leucine supplementation on muscle growth, metabolism, body composition, inflammation and wellbeing in adolescents and young adults with CP.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
25

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Aug 2018

Shorter than P25 for not_applicable

Geographic Reach
1 country

2 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 20, 2018

Completed
Same day until next milestone

Study Start

First participant enrolled

August 20, 2018

Completed
23 days until next milestone

First Posted

Study publicly available on registry

September 12, 2018

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 22, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 22, 2018

Completed
Last Updated

September 12, 2018

Status Verified

August 1, 2018

Enrollment Period

2 months

First QC Date

August 20, 2018

Last Update Submit

September 11, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

  • Skeletal muscle volume

    Change in biceps brachii volume

    10 weeks

Secondary Outcomes (4)

  • Resting metabolic rate

    10 weeks

  • Perceptual well-being questionnaire

    10 weeks

  • Systemic inflammation (C-Reactive protein; C-RP)

    10 weeks

  • Skeletal muscle strength

    10 weeks

Study Arms (2)

Leucine group

EXPERIMENTAL

To receive leucine on a daily basis for 10 weeks

Dietary Supplement: Leucine

Control group

PLACEBO COMPARATOR

To receive a placebo supplement on a daily basis for 10 weeks

Dietary Supplement: Placebo

Interventions

LeucineDIETARY_SUPPLEMENT

192 mg/kg body mass/day

Also known as: Amino Acid
Leucine group
PlaceboDIETARY_SUPPLEMENT

A taste and calorie-matched placebo

Control group

Eligibility Criteria

Age12 Years - 40 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • A diagnosis of spastic cerebral palsy
  • Aged 12-22 years

You may not qualify if:

  • Orthopaedic surgery of the upper-limbs in the past 12 months
  • Botulinum toxin type A injections in the past 6 months
  • Serial casting in the past 6 months
  • Insufficient cognitive understanding to comply with the assessment procedures and intervention
  • Liver and/or kidney dysfunction

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

University of Gloucestershire

Cheltenham, Gloucestershire, GL502RH, United Kingdom

Location

St Marys Umiversity College

London, TW1 4SX, United Kingdom

Location

Related Publications (1)

  • Theis N, Brown MA, Wood P, Waldron M. Leucine Supplementation Increases Muscle Strength and Volume, Reduces Inflammation, and Affects Wellbeing in Adults and Adolescents with Cerebral Palsy. J Nutr. 2021 Jan 4;151(1):59-64. doi: 10.1093/jn/nxaa006.

MeSH Terms

Conditions

Cerebral PalsyCerebral Palsy, Ataxic, Autosomal Recessive

Interventions

LeucineAmino Acids

Condition Hierarchy (Ancestors)

Brain Damage, ChronicBrain DiseasesCentral Nervous System DiseasesNervous System Diseases

Intervention Hierarchy (Ancestors)

Amino Acids, Branched-ChainAmino Acids, Peptides, and ProteinsAmino Acids, Essential

Study Officials

  • Nicola Theis, PhD

    University of Gloucestershire

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
All parties will be masked from the intervention.
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: The study will be a randomised controlled pilot trial. Participants will complete testing at baseline and after 10 weeks.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 20, 2018

First Posted

September 12, 2018

Study Start

August 20, 2018

Primary Completion

October 22, 2018

Study Completion

October 22, 2018

Last Updated

September 12, 2018

Record last verified: 2018-08

Data Sharing

IPD Sharing
Will not share

Locations